The Use of Wearable Devices in Oncology Patients: A Systematic Review
CONCLUSION: Wearable devices may provide valuable data for the purposes of treatment monitoring, prognostication, and rehabilitation. Future studies should investigate live-time monitoring of collected data, which may facilitate directed interventions.PMID:37971410 | DOI:10.1093/oncolo/oyad305 (Source: The Oncologist)
Source: The Oncologist - November 16, 2023 Category: Cancer & Oncology Authors: Ronald Chow Hannah Drkulec James H B Im Jane Tsai Abdulwadud Nafees Swetlana Kumar Tristan Hou Rouhi Fazelzad Natasha B Leighl Monika Krzyzanowska Philip Wong Srinivas Raman Source Type: research

Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors
Oncologist. 2023 Nov 16:oyad300. doi: 10.1093/oncolo/oyad300. Online ahead of print.ABSTRACTProspective and between trial comparisons indicate that first-line treatment with immune checkpoint inhibitors improves survival outcomes compared to first-line therapy with combined BRAF and MEK inhibitors in metastatic melanoma containing BRAFV600E/K mutations. Long-term outcomes for BRAF/MEK inhibition after progression on immunotherapy have not been reported. Moreover, clinical variables associated with outcome from treatment with combined BRAF/MEK inhibition were previously identified in the first-line setting but have not been...
Source: The Oncologist - November 16, 2023 Category: Cancer & Oncology Authors: Adriana M Kahn Curtis J Perry Katrina Etts Harriet Kluger Mario Sznol Source Type: research

Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial
CONCLUSION: Baseline NLR was independently prognostic of PFS and OS. Low-baseline NLR was associated with numerically better efficacy outcomes, but the benefit of adding abemaciclib to fulvestrant was similar irrespective of baseline NLR status.PMID:37971418 | DOI:10.1093/oncolo/oyad301 (Source: The Oncologist)
Source: The Oncologist - November 16, 2023 Category: Cancer & Oncology Authors: Eriko Tokunaga Yasuo Miyoshi Koji Dozono Tsutomu Kawaguchi Masakazu Toi Source Type: research

Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics
CONCLUSION: Prognostic models derived from the combination of clinicopathological features and peripheral blood indices, such as NLR, represent attractive markers mainly because they are easily detectable and applicable in daily clinical practice. More comprehensive prospective studies are needed to unveil their actual effectiveness.PMID:37971409 | DOI:10.1093/oncolo/oyad303 (Source: The Oncologist)
Source: The Oncologist - November 16, 2023 Category: Cancer & Oncology Authors: Sara Socorro Faria Diana Giannarelli Vladmir Claudio Cordeiro de Lima Sumadi Luckman Anwar Chiara Casadei Ugo De Giorgi Gabriele Madonna Paolo Antonio Ascierto Rossana Veronica Mendoza L ópez Roger Chammas Mariaelena Capone Source Type: research

The Use of Wearable Devices in Oncology Patients: A Systematic Review
CONCLUSION: Wearable devices may provide valuable data for the purposes of treatment monitoring, prognostication, and rehabilitation. Future studies should investigate live-time monitoring of collected data, which may facilitate directed interventions.PMID:37971410 | DOI:10.1093/oncolo/oyad305 (Source: The Oncologist)
Source: The Oncologist - November 16, 2023 Category: Cancer & Oncology Authors: Ronald Chow Hannah Drkulec James H B Im Jane Tsai Abdulwadud Nafees Swetlana Kumar Tristan Hou Rouhi Fazelzad Natasha B Leighl Monika Krzyzanowska Philip Wong Srinivas Raman Source Type: research